Paradoxical roles of alveolar macrophages in the host response to Cryptococcus neoformans

Journal of Infection and Chemotherapy

Volumn 18, Issue 1, 2012, Pages 1-9

  McQuiston, Travis J ^a   Williamson, Peter R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Cryptococcosis; Cryptococcus; Lung disease; Macrophage

Indexed keywords

COPPER DEPENDENT TRANSCRIPTION FACTOR 1; COPPER ZINC SUPEROXIDE DISMUTASE; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; MANGANESE SUPEROXIDE DISMUTASE; PHOSPHOLIPASE; PHOSPHOLIPASE B1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CIR1; TRANSCRIPTION FACTOR CTR4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AUTOPHAGY; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CRYPTOCOCCUS NEOFORMANS; DISEASE PREDISPOSITION; FUNGAL VIRULENCE; FUNGUS TRANSMISSION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTERNALIZATION; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE FUNCTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY CRYPTOCOCCOSIS; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 84863487718     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0306-2     Document Type: Review

References (85)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525-30.
2. Warnock DW. Fungal diseases: an evolving public health challenge. Med Mycol. 2006;44:697-705. (Pubitemid 44824447)
3. Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin N Am 2006;20:507-44, v-vi. (Pubitemid 44375117)
4. Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis. 2008;47:1321-7.
5. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002;16: 1031-8. (Pubitemid 34499426)
6. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4:e21.
7. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291-322.
8. Bennett JE, Kwon-Chung KJ, Howard DH. Epidemiologic differences among serotypes of Cryptococcus neoformans. Am J Epidemiol. 1977;105:582-6. (Pubitemid 8132175)
9. Nishikawa MM, Lazera MS, Barbosa GG, et al. Serotyping of 467 Cryptococcus neoformans isolates from clinical and environmental sources in Brazil: analysis of host and regional patterns. J Clin Microbiol. 2003;41:73-7. (Pubitemid 36098556)
10. Hiremath SS, Chowdhary A, Kowshik T, Randhawa HS, Sun S, Xu J. Long-distance dispersal and recombination in environmental populations of Cryptococcus neoformans var. grubii from India. Microbiology. 2008;154:1513-24.
11. Guillot L, Carroll SF, Homer R, Qureshi ST. Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection. Infect Immun. 2008;76:4745-56.
12. Sanchez-Mejorada G, Rosales C. Signal transduction by immunoglobulin Fc receptors. J Leukoc Biol. 1998;63:521-33. (Pubitemid 28193764)
13. Vecchiarelli A, Dottorini M, Pietrella D, et al. Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection. Am J Respir Cell Mol Biol. 1994;11:130-7.
14. Vecchiarelli A, Pietrella D, Dottorini M, et al. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol. 1994;98:217-23. (Pubitemid 24336816)
15. Vecchiarelli A, Retini C, Monari C, Tascini C, Bistoni F, Kozel TR. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun. 1996;64:2846-9. (Pubitemid 26226860)
16. Abe K, Kadota J, Ishimatsu Y, et al. Th1-Th2 cytokine kinetics in the bronchoalveolar lavage fluid of mice infected with Cryptococcus neoformans of different virulences. Microbiol Immunol. 2000;44:849-55.
17. Arora S, Hernandez Y, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB. Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J Immunol. 2005;174:6346-56. (Pubitemid 40663828)
18. Hernandez Y, Arora S, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB. Distinct roles for IL-4 and IL-10 in regulating T2 immunity during allergic bronchopulmonary mycosis. J Immunol. 2005;174:1027-36. (Pubitemid 40094299)
19. Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect Immun. 2002;70:2959-64. (Pubitemid 34564154)
20. Huffnagle GB, Lipscomb MF, Lovchik JA, Hoag KA, Street NE. The role of CD4? and CD8? T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol. 1994;55:35-42. (Pubitemid 24039583)
21. Okano M, Satoskar AR, Abe M, et al. Interleukin-4-independent production of Th2 cytokines by nasal lymphocytes and nasal eosinophilia in murine allergic rhinitis. Allergy. 2000;55:723-31. (Pubitemid 30619489)
22. Olszewski MA, Huffnagle GB, Traynor TR, McDonald RA, Cook DN, Toews GB. Regulatory effects of macrophage inflammatory protein 1alpha/CCL3 on the development of immunity to Cryptococcus neoformans depend on expression of early inflammatory cytokines. Infect Immun. 2001;69:6256-63. (Pubitemid 32885189)
23. Snelgrove RJ, Edwards L, Williams AE, Rae AJ, Hussell T. In the absence of reactive oxygen species, T cells default to a Th1 phenotype and mediate protection against pulmonary Cryptococcus neoformans infection. J Immunol. 2006;177:5509-16. (Pubitemid 44527624)
24. Voelz K, Lammas DA, May RC. Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect Immun. 2009;77:3450-7.
25. Hill JO. CD4? T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J Exp Med. 1992;175:1685-95.
26. Shibuya K, Hirata A, Omuta J, et al. Granuloma and cryptococcosis. J Infect Chemother. 2005;11:115-22. (Pubitemid 40933677)
27. Olszewski MA, Zhang Y, Huffnagle GB. Mechanisms of cryptococcal virulence and persistence.FutureMicrobiol. 2010;5:1269-88.
28. Guerrero A, Jain N, Wang X, Fries BC. Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation. Infect Immun. 2010;78:1049-57.
29. Muller U, Stenzel W, Kohler G, et al. A gene-dosage effect for interleukin-4 receptor alpha-chain expression has an impact on Th2-mediated allergic inflammation during bronchopulmonary mycosis. J Infect Dis. 2008;198:1714-21.
30. Zhang Y, Wang F, Tompkins KC, et al. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am J Pathol. 2009;175:2489-500.
31. Muller U, Stenzel W, Kohler G, et al. IL-13 induces diseasepromoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J Immunol. 2007;179:5367-77.
32. Hoag KA, Street NE, Huffnagle GB, Lipscomb MF. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am J Respir Cell Mol Biol. 1995;13:487-95.
33. Wormley FL Jr., Perfect JR, Steele C, Cox GM. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun. 2007;75:1453-62. (Pubitemid 46385839)
34. Shao X, Mednick A, Alvarez M, van Rooijen N, Casadevall A, Goldman DL. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol. 2005;175:3244-51. (Pubitemid 41170545)
35. Diamond RD, Bennett JE. Growth of Cryptococcus neoformans within human macrophages in vitro. Infect Immun. 1973;7:231-6.
36. Goldman DL, Lee SC, Mednick AJ, Montella L, Casadevall A. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect Immun. 2000;68:832-8. (Pubitemid 30056543)
37. Feldmesser M, Tucker S, Casadevall A. Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol. 2001;9:273-8. (Pubitemid 32522807)
38. Levitz SM, Nong SH, Seetoo KF, Harrison TS, Speizer RA, Simons ER. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun. 1999;67:885-90. (Pubitemid 29059232)
39. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun. 2009;77: 120-7.
40. Chretien F, Lortholary O, Kansau I, Neuville S, Gray F, Dromer F. Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis. 2002;186:522-30. (Pubitemid 34876262)
41. Kechichian TB, Shea J, Del Poeta M. Depletion of alveolar macrophages decreases the dissemination of a glucosylceramidedeficient mutant of Cryptococcus neoformans in immunodeficient mice. Infect Immun. 2007;75:4792-8. (Pubitemid 47502148)
42. Luberto C, Martinez-Marino B, Taraskiewicz D, et al. Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J Clin Invest. 2003;112:1080-94. (Pubitemid 38056323)
43. McQuiston T, Luberto C, Del Poeta M. Role of host sphingosine kinase 1 in the lung response against cryptococcosis. Infect Immun. 2010;78:2342-52.
44. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol. 1999;37:3204-9. (Pubitemid 29455206)
45. Dromer F, Ronin O, Dupont B. Isolation of Cryptococcus neoformans var. gattii from an Asian patient in France: evidence for dormant infection in healthy subjects. J Med Vet Mycol. 1992;30:395-7.
46. Abadi J, Pirofski L. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. J Infect Dis. 1999;180:915-9. (Pubitemid 29411392)
47. Abadi J, Nachman S, Kressel AB, Pirofski L. Cryptococcosis in children with AIDS. Clin Infect Dis. 1999;28:309-13. (Pubitemid 29241220)
48. Davis J, Zheng WY, Glatman-Freedman A, et al. Serologic evidence for regional differences in pediatric cryptococcal infection. Pediatr Infect Dis J. 2007;26:549-51. (Pubitemid 46847323)
49. Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics. 2001;107:E66.
50. Houpt DC, Pfrommer GS, Young BJ, Larson TA, Kozel TR. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun. 1994;62:2857-64. (Pubitemid 24203971)
51. Casadevall A, Pirofski L. Host-pathogen interactions: the attributes of virulence. J Infect Dis. 2001;184:337-44. (Pubitemid 32662181)
52. Feldmesser M, Kress Y, Novikoff P, Casadevall A. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun. 2000;68:4225-37. (Pubitemid 30434578)
53. Shea JM, Kechichian TB, Luberto C, Del Poeta M. The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect Immun. 2006;74:5977-88. (Pubitemid 44484585)
54. Goldman D, Lee SC, Casadevall A. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun. 1994;62:4755-61. (Pubitemid 24332772)
55. Ma H, Croudace JE, Lammas DA, May RC. Expulsion of live pathogenic yeast by macrophages. Curr Biol. 2006;16:2156-60. (Pubitemid 44692099)
56. Alvarez M, Casadevall A. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol. 2006;16:2161-5. (Pubitemid 44692112)
57. Johnston SA, May RC. The human fungal pathogen Cryptococcus neoformans escapes macrophages by a phagosome emptying mechanism that is inhibited by Arp2/3 complex-mediated actin polymerisation. PLoS Pathog 2010;6(8):pii: e1001041.
58. Levitz SM, Harrison TS, Tabuni A, Liu X. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. J Clin Invest. 1997;100:1640-6. (Pubitemid 27425792)
59. Cherniak R, Morris LC, Belay T, Spitzer ED, Casadevall A. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun. 1995;63:1899-905.
60. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol. 2009;68:133-216.
61. Zaragoza O, Chrisman CJ, Castelli MV, et al. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol. 2008;10:2043-57.
62. Liu L, Tewari RP, Williamson PR. Laccase protects Cryptococcus neoformans from antifungal activity of alveolar macrophages. Infect Immun. 1999;67:6034-9. (Pubitemid 29508134)
63. Zhu X, Gibbons J, Garcia-Rivera J, Casadevall A, Williamson PR. Laccase of Cryptococcus neoformans is a cell wall-Associated virulence factor. Infect Immun. 2001;69:5589-96. (Pubitemid 32786495)
64. Zhu X, Gibbons J, Zhang S, Williamson PR. Copper-mediated reversal of defective laccase in a Deltavph1 avirulent mutant of Cryptococcus neoformans. Mol Microbiol. 2003;47:1007-14. (Pubitemid 36232797)
65. Wagner D, Maser J, Lai B, et al. Elemental analysis of Mycobacterium avium-, Mycobacterium tuberculosis-, and Mycobacterium smegmatis-containing phagosomes indicates pathogeninduced microenvironments within the host cell's endosomal system. J Immunol. 2005;174:1491-500.
66. Serafin-Lopez J, Chacon-Salinas R, Munoz-Cruz S, Enciso-Moreno JA, Estrada-Parra SA, Estrada-Garcia I. The effect of iron on the expression of cytokines in macrophages infected with Mycobacterium tuberculosis. Scand J Immunol. 2004;60:329-37. (Pubitemid 39331489)
67. Pan X, Tamilselvam B, Hansen EJ, Daefler S. Modulation of iron homeostasis in macrophages by bacterial intracellular pathogens. BMC Microbiol. 2010;10:64.
68. Erb-Downward JR, Huffnagle GB. Cryptococcus neoformans produces authentic prostaglandin E2 without a cyclooxygenase. Eukaryot Cell. 2007;6:346-50.
69. Noverr MC, Cox GM, Perfect JR, Huffnagle GB. Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production. Infect Immun. 2003;71:1538-47. (Pubitemid 36254342)
70. Noverr MC, Phare SM, Toews GB, Coffey MJ, Huffnagle GB. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect Immun. 2001;69:2957-63. (Pubitemid 32332188)
71. Odom A, Del Poeta M, Perfect J, Heitman J. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685, 818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother. 1997;41: 156-61. (Pubitemid 26428148)
72. Kozubowski L, Lee SC, Heitman J. Signalling pathways in the pathogenesis of Cryptococcus. Cell Microbiol. 2009;11:370-80.
73. Panepinto JC, Williamson PR. Intersection of fungal fitness and virulence in Cryptococcus neoformans. FEMS Yeast Res. 2006;6:489-98. (Pubitemid 43725733)
74. Fan W, Kraus PR, Boily MJ, Heitman J. Cryptococcus neoformans gene expression during murine macrophage infection. Eukaryot Cell. 2005;4:1420-33. (Pubitemid 41176696)
75. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem. 1995;64:97-112.
76. Cox GM, Harrison TS, McDade HC, et al. Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun. 2003;71:173-80. (Pubitemid 36026018)
77. Narasipura SD, Chaturvedi V, Chaturvedi S. Characterization of Cryptococcus neoformans variety gattii SOD2 reveals distinct roles of the two superoxide dismutases in fungal biology and virulence. Mol Microbiol. 2005;55:1782-800. (Pubitemid 40445213)
78. Garcia J, Shea J, Alvarez-Vasquez F, et al. Mathematical modeling of pathogenicity of Cryptococcus neoformans. Mol Syst Biol. 2008;4:183.
79. Siafakas AR, Sorrell TC, Wright LC, et al. Cell wall-linked cryptococcal phospholipase B1 is a source of secreted enzyme and a determinant of cell wall integrity. J Biol Chem. 2007; 282:37508-14.
80. Siafakas AR, Wright LC, Sorrell TC, Djordjevic JT. Lipid rafts in Cryptococcus neoformans concentrate the virulence determinants phospholipase B1 and Cu/Zn superoxide dismutase. Eukaryot Cell. 2006;5:488-98.
81. Wright LC, Santangelo RM, Ganendren R, Payne J, Djordjevic JT, Sorrell TC. Cryptococcal lipid metabolism: phospholipase B1 is implicated in transcellular metabolism of macrophage-derived lipids. Eukaryot Cell. 2007;6:37-47. (Pubitemid 46147651)
82. Jung WH, Sham A, White R, Kronstad JW. Iron regulation of the major virulence factors in the AIDS-Associated pathogen Cryptococcus neoformans. PLoS Biol. 2006;4:e410.
83. Jung WH, Hu G, Kuo W, Kronstad JW. Role of ferroxidases in iron uptake and virulence of Cryptococcus neoformans. Eukaryot Cell. 2009;8:1511-20.
84. Waterman SR, Hacham M, Hu G, et al. Role of a CUF1/CTR4 copper regulatory axis in the virulence of Cryptococcus neoformans. J Clin Invest. 2007;117:794-802. (Pubitemid 46348538)
85. Hu G, Hacham M, Waterman SR, et al. PI3K signaling of autophagy is required for starvation tolerance and virulence of Cryptococcus neoformans. J Clin Invest. 2008;118:1186-97. (Pubitemid 351364625)